A Phase 4 Single-arm Open-label Study for the Efficacy and Safety of Prolia® in Subjects With Glucocorticoid-induced Osteoporosis in Mainland China
Latest Information Update: 25 Dec 2024
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 27 Dec 2024 Planned primary completion date changed from 14 May 2027 to 27 May 2027.
- 27 Dec 2024 Planned initiation date changed from 10 Apr 2025 to 27 May 2025.
- 19 Dec 2024 Planned End Date changed from 14 May 2027 to 27 May 2027.